Kantarjian et al53 assessed the efficacy and protection of dasatinib, as compared with imatinib, for the very first-line treatment method of CML-CP. Five hundred and nineteen sufferers with recently diagnosed CML-CP have been randomly assigned to receive dasatinib at a dose of one hundred mg when daily (259 individuals) or https://pf-0522130400877.look4blog.com/67725732/the-cyanidin-chloride-diaries